✦ LIBER ✦

Placebo-controlled study of rTMS for the treatment of Parkinson's disease

✍ Scribed by Mikhail P. Lomarev; Sulada Kanchana; William Bara-Jimenez; Meena Iyer; Eric M. Wassermann; Mark Hallett

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 125 KB
Volume: 21
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.20713

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The objective of this study is to assess the safety and efficacy of repetitive transcranial magnetic stimulation (rTMS) for gait and bradykinesia in patients with Parkinson's disease (PD). In a double‐blind placebo‐controlled study, we evaluated the effects of 25 Hz rTMS in 18 PD patients. Eight rTMS sessions were performed over a 4‐week period. Four cortical targets (left and right motor and dorsolateral prefrontal cortex) were stimulated in each session, with 300 pulses each, 100% of motor threshold intensity. Left motor cortex (MC) excitability was assessed using motor evoked potentials (MEPs) from the abductor pollicis brevis. During the 4 weeks, times for executing walking and complex hand movements tests gradually decreased. The therapeutic rTMS effect lasted for at least 1 month after treatment ended. Right‐hand bradykinesia improvement correlated with increased MEP amplitude evoked by left MC rTMS after individual sessions, but improvement overall did not correlate with MC excitability. rTMS sessions appear to have a cumulative benefit for improving gait, as well as reducing upper limb bradykinesia in PD patients. Although short‐term benefit may be due to MC excitability enhancement, the mechanism of cumulative benefit must have another explanation. © 2005 Movement Disorder Society

📜 SIMILAR VOLUMES

Macrogol for the treatment of constipati

Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study

✍ Roberta Zangaglia; Emilia Martignoni; Margaret Glorioso; Maria Ossola; Giulio Ri 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## Abstract Chronic constipation is the most frequent symptom of autonomic system involvement in Parkinson's disease (PD). Quite often the symptom is severe and impairs patients' quality of life. The objective of this study is to determine the efficacy and safety of an isosmotic macrogol solution f

High-frequency rTMS over the supplementa

High-frequency rTMS over the supplementary motor area for treatment of Parkinson's disease

✍ Masashi Hamada; Yoshikazu Ugawa; Sadatoshi Tsuji 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB 👁 1 views

## Abstract Dysfunction of the basal ganglia‐thalamocortical motor circuit is a fundamental model to account for motor symptoms in Parkinson's disease (PD). Using high‐frequency repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA), we investigated whether modu

Treatment of insomnia in Parkinson's dis

Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo

✍ Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin; Michael Gara; Karina Bi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 1 views

## Abstract Parkinson's disease (PD) is a common neurodegenerative disease affecting up to 1 million individuals in the United States. Sleep disturbances, typically in sleep maintenance, are found in up to 88% of these individuals and are associated with a variety of poor outcomes. Despite being co

Comparison of desipramine and citalopram

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double-blind, randomized, placebo-controlled study

✍ David Devos; Kathy Dujardin; Isabelle Poirot; Caroline Moreau; Olivier Cottencin 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 1 views

## Abstract Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants

Safety and efficacy of perampanel in adv

Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study

✍ Karla Eggert; David Squillacote; Paolo Barone; Richard Dodel; Regina Katzenschla 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

Squillacote, received compensation from Eisai for their site's conduct of the study. Drs. Barone, Lees, and Oertel received honoraria from Eisai as members of the Advisory Board of this study. Dr. Rascol has received unrestricted scientific grant and honoraria from Eisai for his advice to the compan

Sarizotan as a treatment for dyskinesias

Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial

✍ Christopher G. Goetz; Philippe Damier; Christine Hicking; Eugene Laska; Thomas M 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

## Abstract The objective of this study is to conduct a dose‐finding study of sarizotan in Parkinson's disease (PD) patients with dyskinesia to identify a safe dose and to identify a sensitive dyskinesia rating measure. Sarizotan is a novel compound with full 5‐HT~1A~ agonist properties and additio